Abstract 1792P
Background
The prognosis of ES SCLC has remained poor since two decades ago when the actual standard of care, cisplatin or carboplatin combined with etoposide (Cisp-E and Carb-E), was established. At the time of the first promising results of immunotherapy in this indication, our study describes patient characteristics, real world treatment strategies and the efficacy of chemotherapies that could eventually be combined with immunotherapy.
Methods
FRESC is a secondary data use study on French national lung cancer clinical databases in non-academic hospitals: KBP-2010 (7051 patients followed during 5 years) and ESCAP-2011 (3943 patients followed during 3 years). 1L ES SCLC target population was defined among both cohorts (796 at initial diagnosis = KBP; 475 at initial diagnosis + during follow-up = ESCAP) to maximize representativeness in French population. A subpopulation of patients meeting the IMpower133 trial inclusion criteria was also defined (394 = KBP IMpower-like). The primary objective was to describe baseline characteristics of patients with untreated ES SCLC.
Results
Patient characteristics were similar between KBP and ESCAP cohorts, with a majority of men (respectively 77 and 76%), similar ECOG PS 0-1 rate (59 and 60%) but differing TNM stage repartitions (stage IV = 85% and 77%). In both cohorts the Cisp-E subgroup patients were younger (median age 61 years for both) and fitter (ECOG PS 0-1 = 75 and 73%) than in the Carb-E subgroup (median age 71 and 70 years; ECOG PS 0-1 = 56 % for both). The 1st therapeutic strategy was predominantly a combination of Etoposide with platinum (Carb-E = 40% and Cisp-E = 37% in KBP; Carb-E = 40% and Cisp-E = 34% in ESCAP). In both populations, median Overall Survival (OS) with Cisp-E was 9.6 and 9.4 months, median OS with Carb-E was 7 months. Overall adjusted median OS of the 375 evaluable patients in the KBP IMpower-like population was 9.4 months (10 and 8.2 months in Cisp-E and Carb-E).
Conclusions
Characteristics and OS of 1L ES SCLC patients treated in non-academic hospitals differ depending on treatment strategy. When applying main population characteristics of IMpower133 to FRESC, efficacy results are closer to the ones that were found in IMpower133 control arm.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Roche S.A.S.
Funding
Roche S.A.S.
Disclosure
D. Debieuvre: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Research grant/Funding (institution): Chugaï; Honoraria (self), Research grant/Funding (institution): Lilly; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): MSD; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Boehringer Ingelheim; Research grant/Funding (institution): Chiesi; Research grant/Funding (institution): Janssen; Research grant/Funding (institution): GSK; Research grant/Funding (institution): Sandoz; Travel/Accommodation/Expenses: MundiPharma; Travel/Accommodation/Expenses: Pierre Fabre. A. Dixmier: Honoraria (self): Roche; Honoraria (self): Novartis; Honoraria (self): BMS. S. Gally, D. Pau, W. Greenwood: Full/Part-time employment: Roche. L. Falchero: Advisory/Consultancy: Roche; Advisory/Consultancy: Boehringer; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: BMS; Advisory/Consultancy: MSD; Advisory/Consultancy: Chiesi; Advisory/Consultancy: GSK; Advisory/Consultancy: Menarini; Advisory/Consultancy: Amgen. All other authors have declared no conflicts of interest.